Mathieu Morand: Insights from World Cancer Series on Healthcare Innovation and Access Misalignment
Private investment incentives in the healthcare sector are fundamentally misaligned with the requirements of public health systems, according to Mathieu Morand, Director of the C/Can Accelerator Hub at the City Cancer Challenge. During the World Cancer Series, industry participants acknowledged that current venture capital metrics prioritize premium markets and affluent populations over addressing systemic access gaps.
The venture capital and private equity industry in healthcare typically operates on an eight-year return on investment (ROI) cycle, which critics argue is insufficient to prioritize long-term public health access goals.
Why Current Investment Models Fail Health Systems
The primary disconnect between private capital and public health lies in the focus on profitability within short timeframes. According to Morand, who previously worked in venture capital, investment deals are often financially sound but fail to address the actual needs of health systems. Because the industry relies on returns from premium markets, innovation in medical technology remains largely accessible only to those who can afford it.
The misalignment described suggests a structural barrier where the speed of innovation outpaces the ability of public systems to adopt it. If financial models do not evolve to value equitable distribution, the gap between cutting-edge medical availability and patient access is likely to widen.
What May Happen Next
The future of sustainable access to medical innovation remains uncertain, as stakeholders consider who should take responsibility for bridging the gap. Potential shifts could involve regulators, entrepreneurs, or international agencies taking a more active role in directing investment. It is possible that future strategies will attempt to embed access requirements directly into the development phase of new technologies to ensure they reach broader populations.
Frequently Asked Questions
What is the main critique of current healthcare venture capital?
The primary critique is that investment incentives are misaligned with public health needs, focusing on premium markets and affluent populations rather than solving access gaps.
Why is the current ROI model problematic for healthcare?
The venture capital industry generally requires a return on investment within eight years, which does not provide enough time to focus on sustainable or equitable access to medical innovation.
Who might be responsible for improving access to innovation?
Questions remain regarding whether the responsibility lies with regulators, entrepreneurs, international agencies, or the entities that buy out innovative businesses.
How can private investment structures be reconfigured to prioritize long-term public health outcomes over short-term financial returns?